CoronaVac provided 83% efficacy against COVID-19 in a Turkish trial and 65.9% effectiveness in a Chilean national vaccine campaign.

In one study, 86% of participants in a single skilled nursing facility were colonized; in another, pan–antifungal-resistant isolates were found at two separate long-term facilities.

Heterologous vaccination yielded robust immune responses, but it remains unclear whether this approach is superior to the two-dose mRNA vaccine regimen.

Treatment guided by bacterial load allowed significantly shorter antibiotic courses and was associated with fewer exacerbations.

The decline in other viral infections has triggered a drop in outpatient antibiotic use for respiratory tract infections.